Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 1998

View Archived Issues

The role of lipopolysaccharide in the induction of IL-1beta secretion

Millennium: Q4 and year-end 1997 highlights

Medeva: year-end 1997 highlights

Corvas: Q4 and year-end 1997 highlights

A new therapeutic target for AD: bleomycin hydrolase

Nippon Kayaku and Signal to develop peripheral neuropathy drugs

Triangle Pharmaceuticals obtains license to L-FMAU for HBV treatment

Chemopotentiating agents in R&D at Nippon Flour Milling

New agents for lowering blood glucose and plasma triglycerides

Phenol derivatives for cardiovascular and lipid disorders

Fujisawa describes Na+/H+ exchange inhibitors

Cell adhesion inhibitors described by Kyowa Hakko

New antiinflammatory and analgesic compounds in development at Roche

Purdue discloses antitumor selenophene compounds

Colchicine analogues from Indena show potential for resistant tumors

Wyeth-Ayerst withdraws Verdia NDA

Zenapax approved in Switzerland

New introduction for Glaxo Wellcome/Otsuka broad-spectrum fluoroquinolone

Neurocrine Biosciences to acquire Northwest Neurologic

U.K. market introduction for Singulair

Mechanism of insulinotropic action of BTS-67582 explored in B-cells

Parkinson's disease drug approved in Europe

Avicidin advances to phase II

Calcium channel blockers vs. ACE inhibitors for hypertension in diabetes

Provigil launched in U.K.

Genetronics establishes subsidiary in France

U.S. patent covers use of MH-1 to deliver thrombolytics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...